Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 765 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... May 12, 2021 New Blood Test Can Screen For Over 50 Cancers June 7, 2021 37-Year-Old Mom Breaks American Marathon Record January 21, 2022 ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ February 3, 2021 Load more HOT NEWS Breast Cancer Survivor’s Family Designs a Holiday Light Show in Her... Dr Ian Walker on Smoking: ‘The killer behind the counter’ EMA Recommends Extension of Therapeutic Indications for Daratumumab Men’s skin cancer rates increase by 50% over decade
